Persistent pulmonary hypertension of the newborn (PPHN) is a major cause of mortality and morbidity, causing a vicious cycle of increasing hypoxia and acidosis responding poorly to conventional ventilatory support. Its management has been revolutionised by the introduction of inhaled nitric oxide therapy [1]. Nitric oxide is derived from the conversion of arginine to citrulline by the enzyme nitric oxide synthase [2]. Although nitric oxide is important in maintaining vasodilata-tion in both the pulmonary and systemic circulation, it has been shown to have a very short half-life in vivo [3] and is then converted to nitrate and nitrite by oxygen and water. These can then react further with water to produce nitrous and nitric acids, but fortunately both react avidly with haemoglobin to produce small quantities of methaemoglobin [4]. The net effect of this is that nitric oxide administered to the airway will have its effect only on the pulmonary circulation avoiding the problems of severe systemic hypotension experienced with tolazoline and systemic prostacycline. There is now an increasing amount of literature on the use of nitric oxide in the treatment of PPHN [5][6][7], and although we do not yet have the results of any randomised controlled trials, physiological studies have shown that this therapy will often reduce pulmonary artery pressure [8], increase pulmonary blood flow and produce dramatic improvements in oxygenation with relatively low concentrations of nitric oxide ( < 20 ppm). Neonatally related conditions where success has been reported include idiopathic PPHN, and PPHN complicating meconium aspiration, diaphragmatic hernia [9] , and respiratory tract infections in children with bronchoul-monary dysplasia [10]. There remains considerable interest in whether PPHN represents a failure of endogenous nitric oxide production. Our studies have shown that over the first 24 h of life, pulmonary artery pressure falls and effective pulmonary blood flow increases without any change in the expired nitric oxide concentration. After that there is a close inverse and direct relationship, respectively. There are also data indicating that infants with PPHN have lower urinary nitrite and nitrate levels [11], metabolites of nitric oxide and a study suggesting that infants developing PPHN Extended Abstracts BiolNeonate 1996;69:165-212 199 tend to have lower blood arginine concentrations than well-matched controls [12]. Anxieties about raised levels of methae-moglobin remain. There have been deaths from methaemoglobinaemia and some racial groups, e.g. Red Indians, have a tendency to low levels of
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